What Is Cagrilintide? FDA Status and CagriSema Explained
The short answer Cagrilintide is a synthetic, long-acting analogue of human amylin, developed by Novo Nordisk. It is not an FDA-approved drug on its own. Novo Nordisk filed for FDA approval in December 2025, but that filing is for a fixed-dose combination product called CagriSema, not for cagrilintide by itself. As of this writing, cagrilintide…
